Shares of G1 Therapeutics (NASDAQ:GTHX) plunged 36% in post-market trading after the company said the independent data monitoring committee overseeing a pivotal Phase 3 study of its breast cancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results